Assessing the Cost Effectiveness of an Incremental Lipid‐Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data

Key Points

• This analysis aims to evaluate the cost effectiveness of an incremental lipid-lowering therapy approach after coronary artery bypass grafting using nationwide data.
• Simulated stepwise lipid-lowering therapy
• Used high-intensity statins and ezetimibe
• Assessed cost outcomes at various willingness-to-pay thresholds
• Few patients required bempedoic acid or PCSK9 inhibitors
• The approach was cost-effective at very low willingness-to-pay thresholds

Abstract